CBD Oil for Sleep and Polycythemia Vera: Aquagenic Pruritus as Sleep-Hygiene Barrier, Erythromelalgia Nocturnal Burning Pain, Hyperviscosity Headache, and Thrombotic Event Vigilance
By PureCraft Editorial Team | PureCraft CBD | Updated October 2026
Polycythemia vera (PV) is a clonal myeloproliferative neoplasm characterized by autonomous overproduction of red blood cells — and often white blood cells and platelets — arising from a JAK2 tyrosine kinase mutation (V617F in greater than ninety-five percent of patients, or JAK2 exon 12 mutations in the remaining PV cases) in a pluripotent hematopoietic stem cell. The JAK2 V617F mutation produces constitutive, growth-factor-independent activation of the JAK-STAT signaling pathway in erythroid progenitors, driving erythrocytosis independent of erythropoietin — the normal oxygen-sensing red cell production regulator. The result is pathologically elevated red cell mass: diagnostic hematocrit criteria are above fifty-two percent in men and above forty-eight percent in women (WHO 2016 criteria), though values of sixty percent or higher occur in undiagnosed or untreated PV. Polycythemia vera is categorized as a myeloproliferative neoplasm (MPN), the same broad classification as systemic mastocytosis (P11-265), essential thrombocythemia (ET), and primary myelofibrosis (PMF), though PV's oncogenic driver (JAK2 V617F) and primary clinical manifestation (red cell excess and hyperviscosity) are entirely distinct from SM's KIT D816V mutation and mast cell proliferation. WHO 2016 diagnostic criteria require the major criterion of bone marrow biopsy showing hypercellularity with trilineage proliferation (panmyelosis) plus JAK2 V617F or JAK2 exon 12 mutation, combined with minor criteria of subnormal serum erythropoietin level — confirming the autonomous, EPO-independent erythropoiesis. Distinguishing PV from secondary polycythemia (reactive erythrocytosis from chronic hypoxia — sleep apnea, COPD, high altitude — or from EPO-secreting tumors) is critical, because secondary polycythemia does not carry the JAK2 mutation and does not share PV's intrinsic hematological disease burden or thrombotic risk profile. PV's clinical burden is dominated by its thromboembolic complications — stroke, transient ischemic attack, deep venous thrombosis, pulmonary embolism, hepatic vein thrombosis (Budd-Chiari syndrome), and portal vein thrombosis — which represent the primary PV mortality cause, arising from both the elevated red cell mass (hyperviscosity-driven thrombosis) and the platelet activation that accompanies the MPN state. Treatment is stratified by thrombotic risk: low-risk PV (age below sixty, no prior thrombosis) managed with phlebotomy to maintain hematocrit below forty-five percent plus low-dose aspirin; high-risk PV (age sixty or above, or prior thrombosis) managed with cytoreductive therapy, predominantly hydroxyurea as first-line followed by ruxolitinib (Jakafi) as the JAK1/2 inhibitor second-line option, both combined with aspirin and phlebotomy. PV prevalence is approximately forty-four to fifty-seven cases per one hundred thousand population, with peak onset in the sixth decade of life, though it can occur at any age including young adults.
Polycythemia vera disrupts sleep through four mechanisms that are distinct from the prior myeloproliferative neoplasm post (SM, P11-265) and unique in this series. The first mechanism — aquagenic pruritus as a sleep-hygiene-specific barrier — is the most pathognomonic PV symptom with a uniquely sleep-relevant trigger: aquagenic pruritus (AP) affects sixty-five to seventy percent of PV patients as intense burning, stinging, or itching itch triggered specifically by contact with water at any temperature, usually peaking within minutes of water exposure and lasting thirty to sixty minutes. The sleep connection is specific: evening bathing and showering — the most standard pre-sleep hygiene ritual in human sleep behavior — directly triggers AP episodes at the precisely the time when the patient is preparing for sleep. This creates a physiological barrier to sleep hygiene: PV patients face a nightly choice between taking an evening shower (triggering a thirty-to-sixty-minute AP episode that delays sleep onset) or forgoing their sleep-hygiene ritual (avoiding the trigger but accepting the cognitive disruption of compromised hygiene). No other condition in this series has a primary symptom mechanistically triggered by a sleep preparatory behavior. The second mechanism — erythromelalgia nocturnal burning extremity pain — is a symptom closely associated with PV and essential thrombocythemia: intense burning pain in the extremities (feet primarily, hands secondary) from microvascular thrombosis of small vessels, dramatically worsened by warmth and recumbency (which increases distal blood pooling and heat concentration in bed). Erythromelalgia forces a characteristic sleep disruption behavior pattern: patients hang their feet off the bed or apply cold packs to their extremities to obtain relief — the cooling behavior fragments sleep architecture and disrupts sleep continuity across the night. The third mechanism — hyperviscosity nocturnal headache from elevated red cell mass — produces nocturnal headache, dizziness, and visual disturbances from the positional physiology of cerebrovascular hyperviscosity in recumbency. The fourth mechanism — thrombotic event vigilance — is the pre-sleep cardiovascular mortality awareness that PV's dominant thromboembolic risk profile imposes on patients who know their elevated red cell and platelet mass produces ongoing stroke, DVT, and PE risk that persists despite treatment. CBD oil addresses the PV-specific sleep mechanisms through its TRPV1 desensitization (aquagenic pruritus — TRPV1 activation on cutaneous sensory neurons by the osmotic/aquaporin-mediated water contact mechanism; erythromelalgia — heat-activated TRPV1 burning pain in extremities), CB2/NF-κB anti-inflammatory pathway (microvascular thrombotic inflammation of erythromelalgia; mast cell component of aquagenic pruritus), adenosine/ENT1 (cerebrovascular adenosine for hyperviscosity headache; vascular adenosine for erythromelalgia microvascular component), and 5-HT1A/FAAH/HPA (thrombotic event vigilance anxiety; the chronic HPA burden of living with a myeloproliferative neoplasm and its thrombotic risk).
CBD Oil and PV Medications: Hydroxyurea, Ruxolitinib, Aspirin, Interferon-Alpha, Busulfan, and the PV Polycythemia Interaction Profile
Hydroxyurea (HU) — the primary cytoreductive agent in PV, renally excreted, no meaningful CBD CYP interaction, clean profile: Hydroxyurea is the first-line cytoreductive agent in high-risk PV — it reduces red cell, white cell, and platelet production by inhibiting ribonucleotide reductase. Hydroxyurea is renally excreted rather than CYP metabolized — essentially no pharmacokinetic CBD interaction. The pharmacodynamic direction (CBD and HU both reducing the cellular inflammatory load of PV — CBD through CB2/NF-κB mechanisms reducing mast cell activation that contributes to aquagenic pruritus; HU through cytoreduction reducing the neoplastic cell burden) is potentially additive at the disease-burden level, not through a direct interaction. Disclosure is still appropriate as a general principle of PV management, but no dose adjustment is anticipated from a pharmacokinetic standpoint.
Ruxolitinib (Jakafi) — JAK1/2 inhibitor for HU-intolerant or HU-inadequate PV, CYP3A4 substrate, moderate CBD interaction requiring physician awareness: Ruxolitinib is the FDA-approved second-line cytoreductive therapy for hydroxyurea-resistant or hydroxyurea-intolerant PV. It is a significant CYP3A4 substrate — CBD's moderate CYP3A4 inhibition can increase ruxolitinib plasma levels, producing greater JAK inhibition (with potential for enhanced cytopenia — anemia, thrombocytopenia — or immune suppression) beyond the prescribed dose. This interaction is less severe than the avapritinib CYP3A4 interaction in SM (P11-265) because ruxolitinib has a wider therapeutic window than avapritinib for its target indication in PV, but physician consultation and monitoring are appropriate. The magnitude of the CBD-ruxolitinib CYP3A4 interaction is comparable in category to the CBD-ivabradine interaction in POTS (P11-266) — moderate, clinically meaningful, requiring awareness and monitoring, but not a hard contraindication.
Aspirin — standard antiplatelet in PV, minimal CYP interaction, platelet function note: Low-dose aspirin (81–100 mg daily) is standard in PV for platelet COX-1 inhibition and antiplatelet effect, reducing thrombotic risk. Aspirin is not CYP-metabolized in the clinically relevant sense — minimal pharmacokinetic CBD interaction. The pharmacodynamic note: CBD has some platelet-modulating properties through CB2 receptors on platelets (CB2 activation modestly reduces platelet aggregation); combining CBD with aspirin in PV may provide additive antiplatelet effect at the pharmacodynamic level. This is generally consistent with PV management intent but warrants disclosure to the managing hematologist, particularly in patients with higher bleeding risk or those on aspirin plus anticoagulation for prior thrombotic events.
Pegylated interferon-alpha (PEG-IFN-α-2a, Pegasys) — IFN for young PV patients or those preferring non-chemotherapy, no significant CYP interaction, clean profile: Pegylated interferon-alpha is increasingly used in younger PV patients and in those preferring non-cytotoxic therapy — it suppresses the JAK2 V617F clone through immunomodulatory mechanisms and can produce molecular remission in some patients. PEG-IFN is primarily cleared by proteolysis and renal filtration rather than CYP enzymes — no significant CBD CYP interaction. Disclosure appropriate; no dose adjustment anticipated.
Phlebotomy — procedure, not a medication, no interaction: Phlebotomy to maintain hematocrit below forty-five percent is standard PV management for all patients. No CBD interaction as it is not a pharmacological agent.
Anticoagulants (warfarin, direct oral anticoagulants — apixaban, rivaroxaban, dabigatran) — used in PV patients with prior thrombotic events, CYP2C9/3A4/P-gp interactions, require physician guidance: PV patients with prior stroke, DVT, or PE are typically anticoagulated in addition to antiplatelet therapy. Warfarin (CYP2C9 substrate, narrow therapeutic index) has a meaningful CBD interaction through CYP2C9 — CBD can increase warfarin plasma levels and INR, increasing bleeding risk. DOACs (apixaban and rivaroxaban are CYP3A4 and P-gp substrates; dabigatran is P-gp substrate but minimal CYP) have CYP3A4 interactions for apixaban and rivaroxaban — moderate CBD interaction. For PV patients on anticoagulation, the prescribing hematologist or thrombologist must be consulted before adding CBD — anticoagulant management in PV is a high-stakes clinical decision and INR/drug-level monitoring applies.
How Polycythemia Vera Disrupts Sleep: The Four PV-Specific Sleep Disruption Channels
1. Aquagenic Pruritus as Sleep-Hygiene Barrier: TRPV1 Water-Contact Itch That Is Triggered by Evening Showering
Aquagenic pruritus (AP) is the most pathognomonic symptom of polycythemia vera — present in sixty-five to seventy percent of PV patients, often preceding PV diagnosis by years — and its relationship to sleep is uniquely direct among all symptoms in this series: the primary trigger is water contact, and the primary setting in which water contact is behaviorally expected as a pre-sleep preparation is the evening shower or bath. The mechanism of aquagenic pruritus in PV involves several interacting pathways that distinguish it from ordinary itch. TRPV1 activation on cutaneous sensory neurons is a central mechanism: in PV, the elevated red cell mass, abnormal platelet activation, and mast cell dysregulation (mast cells are increased in PV bone marrow and skin, consistent with the MPN state affecting multiple lineages) produce a sensitized cutaneous sensory environment in which TRPV1 and histamine H1 receptors on skin sensory neurons are tonically sensitized. Water contact — particularly temperature-change water contact (cold or hot water touching sensitized skin) — activates TRPV1-expressing osmosensitive neurons in the skin through aquaporin-mediated osmotic signaling and thermal receptor activation. In the sensitized PV skin environment, this TRPV1 activation produces the characteristic burning, stinging, or itching itch that is disproportionate to the mild stimulus (water contact) — a phenomenon of peripheral sensitization identical in mechanism to TRPV1 sensitization in IC/BPS (P11-263, where gentle bladder filling triggers pain disproportionate to the stimulus) but located on the skin surface and triggered by water. The mast cell component of AP is well-supported: PV mast cells in skin degranulate in response to water contact and the accompanying osmotic/thermal stimulus, releasing histamine and prostaglandins that activate H1 and EP receptors on nearby TRPV1-sensitized sensory neurons, producing the itch cascade. The sleep-disruption mechanism is the most behaviorally specific in the series: evening shower before bed → aquagenic pruritus episode → thirty-to-sixty minutes of intense skin itching → delayed sleep onset, skin scratching behavior, anxiety about the upcoming sleep attempt → impaired sleep onset with residual skin sensitization during early sleep. PV patients adapt by timing showers in the morning (trading sleep-onset disruption for the trade-off of morning AP interfering with morning function), forgoing showers entirely, or using antihistamine pretreatment before evening bathing — each adaptation carrying its own functional cost. CBD oil addresses the aquagenic pruritus mechanism through two channels: TRPV1 desensitization, the most directly relevant mechanism — CBD desensitizes TRPV1 on cutaneous sensory neurons through repeated activation/desensitization cycling, reducing the gain of water-contact-triggered TRPV1 signaling over time and with consistent use; and CB2 mast cell stabilization, reducing the skin mast cell degranulation component of AP that provides the histamine and prostaglandin amplification of the TRPV1-triggered itch. The Cream applied topically to the skin regions most prone to AP (upper extremities, trunk, lower extremities depending on shower exposure pattern) provides the most direct local TRPV1 and CB2 mechanism at the aquagenic pruritus site before the evening shower — a pre-shower topical TRPV1 desensitization application that reduces the magnitude of the subsequent water-contact AP response.
2. Erythromelalgia Nocturnal Burning Extremity Pain: Heat-Activated TRPV1 and Microvascular Thrombotic Inflammation Disrupted by Bed Warmth and Recumbency
Erythromelalgia — episodic intense burning pain, warmth, and erythema of the extremities (predominantly feet, sometimes hands) from microvascular occlusion — is a well-characterized symptom associated with myeloproliferative neoplasms, particularly PV and essential thrombocythemia. The pathophysiology of MPN-associated erythromelalgia is thrombocythemia-driven platelet activation producing microvascular platelet thrombi in small vessels of the extremities (arterioles and venules), with an associated inflammatory response (prostaglandin release, histamine, inflammatory cytokines) that sensitizes local TRPV1-expressing sensory neurons in the skin and small vessel walls. The result is a pain state in which normal warmth — the physiological warmth of the foot in bed, under covers — activates sensitized TRPV1 on the extremity sensory neurons and produces burning pain disproportionate to the mild thermal stimulus. This is precisely the mechanism of TRPV1 thermal allodynia described throughout this series (IC/BPS P11-263, MCAS P11-264), but localized to the extremities and driven by microvascular thrombotic inflammation as the sensitizing event rather than central sensitization or mucosal inflammation. The nocturnal exacerbation of erythromelalgia is both thermal and postural: thermal — bed warmth from bedding and body heat raises local temperature in the extremities above the TRPV1 activation threshold for sensitized neurons, producing burning pain that is absent or minimal at rest during the day at ambient temperature; postural — recumbency increases venous pooling in the lower extremities, raising local microvascular pressure and promoting the platelet aggregation and small vessel stasis that drives erythromelalgia. The characteristic patient behavior is uniquely sleep-disruptive: erythromelalgia relief requires cooling (hanging feet over the side of the bed, applying cold packs, standing on a cold floor, removing socks and exposing feet to air conditioning) — each cooling behavior requires movement and interrupts sleep architecture, and the relief is temporary (the feet warm again in bed, triggering the next erythromelalgia episode). In moderate-to-severe erythromelalgia, patients may have multiple cooling awakenings per night, producing severe sleep fragmentation. CBD addresses erythromelalgia through TRPV1 desensitization (directly reducing the thermal allodynia that makes warm bed temperature painful) and CB2/NF-κB anti-inflammatory reduction of the microvascular inflammatory milieu (histamine, prostaglandins, cytokines) that sustains TRPV1 sensitization in the extremity tissues. The Cream applied topically to the feet (and hands if affected) before bed — the most anatomically specific erythromelalgia application in the series — provides direct local TRPV1 desensitization and CB2 activation at the primary erythromelalgia site, preemptively reducing the TRPV1 sensitization gain before the bed-warmth thermal stimulus activates the burning pain response. Aspirin (which the PV patient is likely already taking) acts through COX-1-mediated prostaglandin reduction at the platelet level — a mechanism complementary to CBD's CB2/NF-κB cytokine reduction at the tissue inflammation level, addressing erythromelalgia from two different points in the same inflammatory cascade.
3. Hyperviscosity Nocturnal Headache: Cerebrovascular Adenosine, Trigeminal TRPV1, and Positional Cerebral Venous Drainage Impairment From Elevated Red Cell Mass
Elevated red cell mass in polycythemia vera increases whole blood viscosity in proportion to hematocrit (at hematocrit sixty percent, blood viscosity is approximately twice that at normal hematocrit forty-five percent), producing the hyperviscosity syndrome that drives PV's cerebrovascular symptoms: headache, dizziness, tinnitus, visual changes, and cognitive impairment. These symptoms are recognizable as the PV constellation to experienced clinicians and are the presenting complaint in a significant minority of newly diagnosed PV patients. The nocturnal character of PV headache has a positional physiology with some mechanistic overlap with IIH (P11-262) — though through different mechanisms. In IIH, recumbent position impairs CSF drainage and raises intracranial CSF pressure. In PV, the mechanism is distinct: recumbency impairs cerebral venous drainage of hyperviscous blood from the brain (the higher-viscosity blood drains more slowly through the cerebral venous system; recumbent position reduces the gravitational assistance to drainage that upright position provides, and the venous drainage of the cerebral sinuses is optimized by upright posture). The result is increased cerebral blood volume during sleep in the hyperviscous PV patient, producing headache during or after sleep from intracranial venous congestion. This positional cerebrovascular hyperviscosity headache is distinct from IIH in mechanism (viscosity rather than CSF pressure) and distinct from POTS hyperviscosity-headache risk in mechanism (PV red cell mass excess versus POTS hypotensive venous pooling). CBD addresses PV hyperviscosity nocturnal headache through adenosine/ENT1 cerebrovascular regulation (adenosine is a potent cerebral vasodilator through A2A receptors on cerebral vessel smooth muscle — CBD's elevation of extracellular adenosine promotes cerebrovascular vasodilation, which provides some compensation for the increased venous resistance from hyperviscosity-impaired drainage) and TRPV1 on trigeminal afferents (trigeminal TRPV1 desensitization reduces the headache pain amplification from intracranial venous congestion through the same trigeminal pain gate mechanism relevant in IIH and cluster headache). This is the third post where trigeminal TRPV1 is the headache mechanism (following IIH and cluster headache), but the upstream driver — hyperviscous blood slowing cerebral venous drainage in recumbency — is unique to PV in the series.
4. Thrombotic Event Vigilance: 5-HT1A and FAAH/HPA for Pre-Sleep Cardiovascular Mortality Awareness in PV's Dominant Thromboembolic Risk Profile
Polycythemia vera's primary clinical burden is thromboembolic: stroke, TIA, DVT, PE, portal vein thrombosis, and hepatic vein thrombosis (Budd-Chiari) — these thrombotic events are the leading cause of PV morbidity and mortality, and they can occur even in treated, well-managed PV. PV patients on aspirin and hydroxyurea live with the knowledge that their elevated red cell mass, platelet activation, and MPN-driven endothelial dysfunction produce persistent thrombotic risk that is reduced but not eliminated by treatment. This persistent, incompletely-suppressible thrombotic risk creates a specific form of pre-sleep cardiovascular mortality vigilance — awareness that during sleep, the reduced circulation of low-cardiac-output sleep, combined with the hyperviscosity of elevated hematocrit and the platelet activation of MPN, produces conditions that favor thrombus formation. PV patients with prior TIA or stroke carry the additional conditioning of knowing the cardiovascular event can occur without warning, and that sleep is a validated high-risk period for stroke (multiple epidemiological studies confirm morning-peak and sleep-onset-period stroke risk elevation — the PV patient's awareness of this epidemiology, accurate as it is, adds a factual substrate to the thrombotic event vigilance that is absent from conditions where the feared event is less directly linked to the sleep period). The thrombotic event vigilance of PV shares its general cognitive structure with the anaphylaxis vigilance of MCAS (P11-264) and the mortality-awareness existential anxiety of systemic mastocytosis (P11-265) — events with real, disease-intrinsic risk that cannot be cognitively dismissed — but its specific content (cardiovascular/neurological events, stroke, clot) and its sleep-period specificity (the morning-peak stroke epidemiology) distinguish it from both prior conditions. 5-HT1A partial agonism addresses the amygdala-driven hypervigilance that amplifies accurate thrombotic risk knowledge into catastrophic pre-sleep rumination — the 5-HT1A mechanism modulates threat-magnitude amplification without inducing denial of the actual risk, allowing the patient to hold their real cardiovascular risk awareness in cognitive balance rather than catastrophic vigilance. FAAH/anandamide normalization and HPA axis modulation address the chronic cortisol elevation and HPA allostatic load from persistent MPN-associated mortality-frame living.
PV Risk Stratification and Disease Control: CBD Protocol Relevance
| PV Profile | Primary Sleep Disruptors | CBD Mechanism Priority | Protocol Note |
|---|---|---|---|
| Low-risk PV on phlebotomy + aspirin — hematocrit managed, no cytoreduction | Aquagenic pruritus as primary sleep-onset barrier (evening shower trigger); erythromelalgia nocturnal burning if platelet count elevated; thrombotic event vigilance from new-diagnosis PV awareness; hyperviscosity headache if hematocrit not yet controlled | TRPV1 (Cream pre-shower, Oil systemic) for AP and erythromelalgia; 5-HT1A for new-diagnosis thrombotic vigilance; adenosine for hyperviscosity headache; CB2/NF-κB for mast cell AP component | Cleanest drug interaction profile in PV — aspirin minimal CYP, phlebotomy no interaction. The pre-shower topical Cream protocol is the most distinctive PV-specific CBD application timing in the series. Low-dose aspirin + CBD combined antiplatelet pharmacodynamics: physician disclosure appropriate though direction is generally consistent with PV management intent. |
| High-risk PV on hydroxyurea + aspirin — cytoreductive therapy | Aquagenic pruritus (may partially improve with HU cytoreduction but persists in many patients); erythromelalgia if thrombocythemia persists; thrombotic vigilance with prior event history; hydroxyurea-associated fatigue compounding sleep quality; mouth sores/GI symptoms from HU affecting sleep | TRPV1 for AP and erythromelalgia; 5-HT1A for thrombotic vigilance (prior event post-traumatic component); FAAH/HPA for HU fatigue and chronic MPN allostatic load; CB2/NF-κB for residual inflammatory mast cell AP component | Hydroxyurea: clean CBD interaction (renally cleared). HU can partially reduce AP and erythromelalgia by reducing the neoplastic cell burden driving mast cell activation and platelet-driven microvascular inflammation — CBD's TRPV1 and CB2 mechanisms address the residual AP and erythromelalgia that persists despite HU. Combined HU cytoreduction + CBD TRPV1/CB2 may provide more AP relief than either alone through complementary mechanisms. |
| HU-resistant or HU-intolerant PV on ruxolitinib | Ruxolitinib often provides excellent AP relief (JAK2 inhibition reduces the mast cell and inflammatory signaling driving AP) but does not eliminate all sleep disruption; ruxolitinib-associated anemia (from JAK2 inhibition of erythropoiesis) may produce fatigue-related sleep quality changes; erythromelalgia may persist if platelet count not fully normalized | FAAH/HPA and 5-HT1A for the thrombotic vigilance and MPN mortality-awareness; adenosine for residual hyperviscosity headache; D9 in CBN Gummies for slow-wave sleep depth in ruxolitinib-treated fatigue | Most important drug interaction in PV medication profile: Ruxolitinib is a CYP3A4 substrate — CBD moderate CYP3A4 inhibition can increase ruxolitinib plasma levels. Hematologist consultation required before adding CBD in ruxolitinib-treated PV. Monitor for enhanced cytopenia (anemia, thrombocytopenia) indicating elevated ruxolitinib exposure. Starting with a lower CBD dose and gradual titration is appropriate; full mechanism benefit is maintained at lower doses because the relevant CBD mechanisms (TRPV1, 5-HT1A, adenosine) do not require high serum CBD concentrations. |
| PV post-thrombotic event (prior stroke, DVT, PE) — on anticoagulation | Post-thrombotic PTSD component (prior cardiovascular event while asleep or detected upon awakening — the morning-peak stroke pattern — producing acute trauma around the sleep period itself); ongoing thrombotic vigilance compounded by prior event; anticoagulation-associated bleeding concerns adding second vigilance layer; sleep architecture disruption from the neurological sequelae of prior stroke if applicable | 5-HT1A for post-thrombotic event PTSD and sleep-period-associated anxiety (most analogous to the MCAS anaphylaxis fear — a prior life-threatening cardiovascular event during sleep producing conditioned fear of the sleep period itself); FAAH/HPA for chronic post-event HPA burden; adenosine for continued hyperviscosity management; TRPV1 for ongoing AP and erythromelalgia | Highest-priority physician disclosure in PV: Patients anticoagulated with warfarin (CYP2C9 narrow therapeutic index) or DOACs (apixaban/rivaroxaban CYP3A4) require hematologist/thrombologist consultation before CBD. INR monitoring for warfarin users is essential when adding CBD. This population has the most complex interaction profile in PV and should not add CBD without specialist guidance. |
Population Profiles
Aquagenic Pruritus-Dominant PV Sleep Protocol: Pre-Shower Topical TRPV1 Desensitization, Systemic CB2 Mast Cell Stabilization, and 5-HT1A Thrombotic Vigilance Coverage
For PV patients whose primary sleep disruption is aquagenic pruritus triggered by the evening shower — the most pathognomonic PV sleep mechanism in the series — the protocol centers on TRPV1 desensitization and CB2 mast cell stabilization with the unique pre-shower topical application timing. The Nano CBD Muscle and Joint Cream applied to the skin areas most exposed during showering (arms, legs, trunk) fifteen to twenty minutes before the evening shower provides the most direct pre-exposure TRPV1 desensitization at the aquagenic pruritus site — preemptively reducing the TRPV1 sensory gain that water-contact activates. This pre-shower topical application timing is unique in this series: no other condition requires topical CBD application before a behavioral trigger in the way that PV aquagenic pruritus requires pre-shower Cream. The Nano CBD Broad Spectrum Oil taken sixty to ninety minutes before the evening shower (timed to peak during and after the shower window) provides systemic TRPV1 desensitization, CB2 mast cell stabilization, 5-HT1A anxiolytic coverage for the shower-anticipation anxiety, and adenosine/HPA support. The Nano CBD Water-Soluble Broad Spectrum Softgels provide overnight sustained coverage for erythromelalgia, hyperviscosity headache modulation, and continued CB2/TRPV1 support through the night. The CBD+CBN+D9+Melatonin Gummies provide melatonin for sleep-onset against the residual AP arousal after the shower, CBN for return-to-sleep after erythromelalgia or AP-related nocturnal awakenings, and D9 for deep sleep restoration in PV chronic sleep deprivation. The Nano CBD Broad Spectrum Gummies maintain daytime CB2/TRPV1 baseline, reducing cumulative skin sensitization that amplifies evening AP. The Nano CBD Full Spectrum Berry Gummies provide enhanced 5-HT1A and terpene entourage for the thrombotic vigilance and MPN mortality-awareness. The Nano CBD Elderberry Gummies extend antioxidant and quercetin mast cell-stabilizing support complementary to CB2 in the AP mast cell component — quercetin has documented mast cell stabilizing properties that are mechanistically additive to CB2 activation in reducing cutaneous mast cell degranulation.
Erythromelalgia-Dominant PV Sleep Protocol: Foot-Targeted Topical TRPV1 Desensitization, Adenosine Microvascular Support, and Deep Sleep Restoration for Fragmented Cooling-Behavior Sleep Architecture
For PV patients whose primary sleep disruption is erythromelalgia nocturnal burning foot pain — with the characteristic cooling behavior (feet off bed, cold packs) fragmenting sleep architecture — the protocol centers on TRPV1 desensitization and microvascular anti-inflammatory coverage targeting the feet specifically. The Nano CBD Muscle and Joint Cream applied generously to both feet (soles, dorsum, ankles) before bed is the most anatomically specific topical application in the PV protocol — the feet are the primary erythromelalgia site, and topical Cream application provides direct TRPV1 desensitization and CB2 anti-inflammatory action precisely where the burning pain is generated. The application is timed before the feet warm under bedding (not after the burning begins) — a pre-emptive TRPV1 desensitization rather than a reactive application. The Nano CBD Broad Spectrum Oil provides systemic TRPV1, CB2/NF-κB, and adenosine coverage for the microvascular thrombotic inflammation of erythromelalgia and the AP component. The CBD+CBN+D9+Melatonin Gummies are specifically targeted at the erythromelalgia sleep fragmentation pattern: D9's slow-wave sleep enhancement addresses the deep sleep deficit from chronic cooling-behavior sleep fragmentation; CBN addresses return-to-sleep after erythromelalgia awakenings when the patient has cooled their feet and returned to bed. The Nano CBD Water-Soluble Broad Spectrum Softgels extend overnight coverage. The Nano CBD Full Spectrum Berry Gummies provide 5-HT1A support for thrombotic vigilance anxiety, and for the anticipatory anxiety of knowing another erythromelalgia episode will likely occur in bed that night. Behavioral complement: keeping bedding as light as possible (reduced thermal insulation at feet), sleeping with feet slightly elevated on a thin pillow (reduces venous pooling that promotes platelet aggregation in the foot vessels), and using a fan directed at the feet (cooling the ambient temperature around the feet below the erythromelalgia thermal threshold) can reduce the frequency and severity of nocturnal erythromelalgia episodes independent of CBD.
CBD Oil Protocol for PV Sleep Disruption
The PV Protocol: Hematologist Disclosure With Ruxolitinib and Anticoagulant Priority, Pre-Shower Cream Timing as the Unique PV Application Protocol, and Aquagenic Pruritus Score + Erythromelalgia Frequency + PSQI Tracking
Hematologist disclosure — ruxolitinib CYP3A4 and anticoagulant interactions as the highest-priority PV drug interactions: PV is managed by hematologists and hematologic oncologists. CBD disclosure should prioritize: ruxolitinib if prescribed (CYP3A4 moderate interaction — physician awareness and monitoring for enhanced cytopenia); anticoagulants if prescribed for prior thrombotic events (warfarin CYP2C9 narrow therapeutic index, highest priority in PV; DOACs CYP3A4 moderate). Hydroxyurea (renally cleared), aspirin (minimal CYP), interferon-alpha (proteolytic clearance), and phlebotomy (procedure) have clean or minimal CBD interaction profiles and do not require dose adjustment, though disclosure to the managing hematologist is appropriate as a general principle. The additive antiplatelet direction of aspirin + CBD should be noted, particularly for patients with bleeding risk factors. For patients not on ruxolitinib or anticoagulation, the PV CBD interaction profile is among the cleaner profiles in the myeloproliferative neoplasm section of this series.
Pre-shower topical Cream application — the unique PV timing protocol for aquagenic pruritus prevention: The pre-shower Cream application fifteen to twenty minutes before the evening shower is the most condition-specific timing protocol in the series. This timing is designed to achieve local TRPV1 desensitization at the skin level before the water-contact trigger, rather than applying Cream reactively after AP symptoms have begun. The aquagenic pruritus episode, once triggered, runs its course largely independent of topical interventions applied after onset — TRPV1 activation produces a self-perpetuating itch/scratch cycle that requires the pre-sensitization-reduction approach rather than a reactive interruption. The systemic Oil should be taken at the same time as the Cream application (sixty to ninety minutes before planned sleep, which is typically thirty to forty minutes before or at shower time), so that the systemic CB2 and TRPV1 mechanisms are active during the shower. AP diary: recording pre-shower Cream use and the resulting AP episode severity (0–10 visual analog scale) over two to four weeks provides the most direct evidence of whether the TRPV1 desensitization protocol is reducing AP episode severity. Many PV patients with AP find that consistent daily TRPV1 desensitization (not just pre-shower use but also morning and afternoon topical applications that maintain ongoing TRPV1 desensitization) produces a cumulative reduction in AP sensitivity over weeks — consistent with the progressive TRPV1 desensitization mechanism that requires repeated receptor activation cycles.
Aquagenic pruritus severity score + erythromelalgia episode frequency + PSQI: PV sleep tracking uses condition-specific symptom scores alongside PSQI. Aquagenic pruritus severity: a simple 0–10 VAS score of AP severity after the evening shower, recorded nightly in an AP diary, provides the most direct CBD response signal for the AP mechanism. Erythromelalgia: nocturnal erythromelalgia episode frequency (number of cooling awakenings per night requiring feet off bed or cold pack application) is the most direct erythromelalgia tracking metric. PSQI at four and eight weeks captures the integrated sleep quality improvement from all four PV mechanisms combined. The target response trajectory: AP score reduction within four weeks (TRPV1 desensitization accumulates progressively), erythromelalgia cooling-awakening frequency reduction within four to six weeks (CB2/NF-κB anti-inflammatory response is somewhat slower), PSQI improvement by eight weeks reflecting integration of both symptom improvements into improved sleep architecture and duration.
PureCraft Products for PV Sleep Disruption
TRPV1 Desensitization, CB2 Mast Cell Stabilization, Adenosine Microvascular and Cerebrovascular, 5-HT1A Thrombotic Vigilance: The PV Mechanism Stack
The Nano CBD Muscle and Joint Cream applied pre-shower (aquagenic pruritus prevention) and to feet before bed (erythromelalgia prevention) is the most central topical product in the PV protocol — its dual application timing for two distinct TRPV1-mediated PV symptoms is unique in this series. The Nano CBD Broad Spectrum Oil provides the systemic multi-mechanism coverage (TRPV1, CB2/NF-κB, adenosine, 5-HT1A, FAAH/HPA) for all four PV sleep disruption channels. The Nano CBD Water-Soluble Broad Spectrum Softgels extend overnight TRPV1 and anti-inflammatory coverage through the full nocturnal erythromelalgia window. The CBD+CBN+D9+Melatonin Gummies provide melatonin sleep-onset against AP arousal, CBN for return-to-sleep after erythromelalgia awakenings, and D9 for deep sleep architecture restoration in PV chronic sleep deprivation. The Nano CBD Full Spectrum Berry Gummies deliver enhanced 5-HT1A and terpene entourage for thrombotic vigilance and MPN mortality-awareness anxiety. The Nano CBD Broad Spectrum Gummies maintain daytime TRPV1 desensitization baseline. The Nano CBD Elderberry Gummies provide quercetin mast cell-stabilizing and antioxidant support complementary to CB2 in the AP mast cell degranulation component.
Frequently Asked Questions About CBD Oil for Polycythemia Vera Sleep
Does CBD oil help with aquagenic pruritus from PV that keeps me from taking an evening shower before bed?
Aquagenic pruritus is one of the most difficult-to-treat PV symptoms, with antihistamines providing partial relief in some patients, aspirin providing benefit in some (through prostaglandin reduction), and ruxolitinib providing the most consistent AP relief through JAK2 pathway inhibition. CBD oil addresses aquagenic pruritus through two mechanisms that are upstream of the histamine/antihistamine pathway that many PV patients have already tried. The primary CBD mechanism for AP is TRPV1 desensitization: CBD reduces the sensitivity of TRPV1-expressing sensory neurons in the skin to the water-contact stimulus that triggers AP. This is not an antihistamine mechanism — it operates on the sensory neuron TRPV1 receptor that converts the water-contact stimulus into itch-signaling nerve impulses, reducing the gain of this conversion. The secondary mechanism is CB2 mast cell stabilization: the mast cells in PV skin that degranulate in response to water contact and release histamine and prostaglandins (the amplification step in AP) are reduced in their degranulation response by CB2 activation. These two mechanisms are most effectively combined by the pre-shower topical Cream approach (TRPV1 desensitization at the skin surface immediately before the trigger) combined with systemic Oil (CB2 mast cell stabilization from within, plus systemic TRPV1 reduction). The key expectation-setting point is that TRPV1 desensitization is a cumulative, progressive process — not an immediate blockade like an antihistamine. Regular daily Cream application (not just pre-shower, but also morning and daytime applications to maintain progressive TRPV1 desensitization) produces a gradual reduction in TRPV1 sensitization over two to four weeks. Tracking AP severity with a nightly 0–10 score after showers for four weeks provides the clearest signal of whether the TRPV1 desensitization protocol is reducing PV-associated AP severity.
Does CBD oil help with the burning foot pain (erythromelalgia) that wakes me up at night and forces me to cool my feet?
Erythromelalgia in PV is a TRPV1-mediated pain state at its sensory end — the burning pain is produced by heat-activated TRPV1 on extremity sensory neurons that have been sensitized by the microvascular thrombotic inflammation of MPN-associated platelet activation. CBD oil addresses this pain mechanism through two complementary pathways. TRPV1 desensitization: CBD desensitizes the sensitized TRPV1 on foot sensory neurons, raising the temperature threshold at which TRPV1 activation produces burning pain — in practical terms, the temperature of bed warmth becomes less likely to cross the reduced TRPV1 activation threshold after progressive desensitization. This mechanism is why the pre-bed topical Cream application to feet (before the feet warm under bedding) is more effective than applying Cream reactively after the burning begins — TRPV1, once activated, produces a self-amplifying pain signal that is harder to interrupt than to prevent. CB2/NF-κB: The platelet-driven microvascular thrombotic inflammation that sensitizes TRPV1 in the first place — the prostaglandins, histamine, and inflammatory cytokines released at the erythromelalgia site — is reduced by CBD's CB2 activation, which suppresses NF-κB-driven inflammatory cytokine production in microvascular endothelial cells and local macrophages. Over four to eight weeks of consistent CB2/NF-κB suppression, the inflammatory milieu maintaining TRPV1 sensitization at the erythromelalgia site is progressively reduced. This CB2/NF-κB mechanism is slower than the direct TRPV1 desensitization mechanism but produces more durable sensitization reduction. The aspirin that most PV patients are already taking provides a COX-1 prostaglandin-reduction mechanism at the platelet level that is complementary to CBD's CB2 anti-inflammatory action — both reduce the inflammatory amplification of erythromelalgia TRPV1 sensitization through different points in the same pathway. The return-to-sleep component after cooling-behavior awakenings is specifically addressed by CBN in the CBN+Melatonin Gummies — after the patient has cooled their feet and the burning pain has subsided, CBN's GABA-modulatory mechanism facilitates returning to sleep more rapidly than waiting for natural sleep-onset to recur.
Does CBD oil interact with my hydroxyurea or ruxolitinib for PV?
The PV medication interaction profile is straightforward for hydroxyurea and more clinically meaningful for ruxolitinib. Hydroxyurea: renally excreted rather than CYP metabolized — no pharmacokinetic CBD interaction. Hydroxyurea's dose is not expected to change from CBD addition, and CBD and hydroxyurea operate through entirely different mechanisms (HU through ribonucleotide reductase inhibition reducing neoplastic cell production; CBD through CB2/TRPV1 reducing the symptoms those cells produce). Physician disclosure is appropriate as a general principle, but no dose adjustment is anticipated. Ruxolitinib: this is the meaningful interaction in the PV cytoreductive medication profile. Ruxolitinib is a CYP3A4 substrate, and CBD's moderate CYP3A4 inhibition (which increases with CBD dose and with fat-rich co-administration) can increase ruxolitinib plasma concentrations. Higher ruxolitinib levels produce enhanced JAK inhibition — which in the efficacy direction means more cytoreduction (potentially beneficial) but in the toxicity direction can produce greater cytopenias (anemia, thrombocytopenia, neutropenia). For PV patients already maintained at a specific ruxolitinib dose with stable counts, adding CBD can alter this equilibrium toward greater cytopenia. The practical guidance for ruxolitinib-treated PV patients adding CBD: consult the managing hematologist before beginning, start with a lower CBD dose than you would otherwise (to minimize the CYP3A4 inhibition magnitude while still getting CBD's mechanism benefits), and schedule a CBC check four to six weeks after beginning CBD to assess whether ruxolitinib-associated cytopenias have changed. If counts are stable or improved, the CBD dose can be gradually titrated to the full intended dose under continued monitoring.
Does CBD oil help with the headaches from polycythemia vera that occur at night or in the morning?
PV headache is multimechanistic — driven by hyperviscosity-impaired cerebral venous drainage, platelet-derived inflammatory mediators acting on intracranial vasculature, and at very high hematocrit values, direct cerebrovascular hypoperfusion from viscosity-impaired flow — and CBD's relevant mechanisms address several of these drivers. Adenosine/ENT1 cerebrovascular vasodilation: CBD's elevation of extracellular adenosine via ENT1 blockade promotes cerebral vasodilation through A2A receptors on cerebral vessel smooth muscle — this vasodilation partially compensates for the increased cerebrovascular resistance imposed by hyperviscous blood, improving cerebral blood flow and venous drainage. The adenosine mechanism is most immediately relevant when the headache correlates with hematocrit elevation (before a phlebotomy session, or in inadequately controlled PV). TRPV1 trigeminal afferent desensitization: PV headache, once present, engages the trigeminovascular pain pathway (the same pathway responsible for migraine-type headache) — CB1 and TRPV1 on trigeminal afferents modulate the pain transmission from intracranial vascular distension and venous congestion to the brain's pain processing centers. This mechanism is most relevant for the acute pain component of PV headache once triggered. CB2/NF-κB: the platelet-derived inflammatory cytokines that contribute to intracranial vascular inflammation in MPN (PGE2, thromboxane A2) are reduced by CBD's CB2 anti-inflammatory mechanisms, addressing the vascular inflammation component of PV headache beyond the viscosity component. The most important non-CBD PV headache intervention is hematocrit management through phlebotomy — keeping hematocrit consistently below forty-five percent is the primary driver of hyperviscosity headache reduction. CBD's mechanism benefit for PV headache is most valuable in the period between phlebotomy sessions when hematocrit is drifting upward, and in patients whose headache persists despite well-controlled hematocrit (suggesting the inflammatory vascular component rather than pure hyperviscosity).
Does CBD oil help with the anxiety about stroke and blood clots from PV that keeps me awake at night?
The thrombotic event vigilance of PV has a feature that distinguishes it from other disease-associated mortality anxieties in this series: it is accurate. PV patients are at elevated risk for stroke, DVT, PE, and other thrombotic events even on appropriate treatment — the anxiety is not a cognitive distortion but a proportionate response to a real ongoing risk. This matters for how CBD's 5-HT1A mechanism applies to PV thrombotic vigilance: the goal is not to eliminate awareness of thrombotic risk (which would be medically counterproductive — PV patients need to recognize thrombotic symptoms and act immediately) but to modulate the amplitude of the pre-sleep rumination about that risk from catastrophic hypervigilance toward held awareness. The 5-HT1A partial agonist mechanism does this specifically — 5-HT1A activation in the amygdala and prefrontal cortex reduces the amygdala's threat-magnitude amplification (the process that takes accurate risk knowledge and amplifies it into catastrophic rumination) without producing the cognitive blunting or denial of reality that anxiolytics with higher sedative profiles can produce. In practical terms: a PV patient on appropriate treatment who has done everything medically correct to manage their thrombotic risk should be able to hold that awareness ("I've taken my aspirin, my hematocrit is controlled, I've talked to my hematologist") without cycling through catastrophic thrombotic event scenarios for hours before sleep. 5-HT1A modulation — through CBD's partial agonism at this receptor — is the pharmacological mechanism that facilitates this shift from catastrophic vigilance to proportionate awareness. The FAAH/HPA mechanism addresses the chronic HPA axis allostatic load from sustained MPN-associated mortality-frame vigilance over months and years — normalizing the cortisol circadian rhythm that chronic stress disrupts and reducing the morning cortisol awakening response that can trigger another cycle of thrombotic event rumination upon awakening.
How does CBD oil for PV sleep differ from CBD oil for systemic mastocytosis or POTS, and can I use all three protocols if I have overlap?
PV, systemic mastocytosis, and POTS produce entirely distinct sleep disruption mechanisms despite being conditions that can overlap in some patients (PV and other MPNs can be accompanied by reactive mast cell activation; POTS occurs in some PV patients from the autonomic effects of elevated viscosity). The mechanisms are genuinely different: PV leads with TRPV1 aquagenic pruritus (unique to PV in the series) and erythromelalgia (TRPV1 thermal allodynia in extremities); SM leads with KIT D816V clonal mast cell nocturnal events, bone marrow skeletal pain, and hepatosplenomegaly (all absent from PV); POTS leads with position-change tachycardia surges and hyperadrenergic ANS arousal (POTS is a dysautonomia, not a myeloproliferative condition, and its mechanisms do not parallel PV). For a patient with true PV-POTS overlap (occurring most commonly in post-COVID populations where PV-adjacent hematological changes and dysautonomia coexist, or in rare PV patients with autonomic nerve involvement from hyperviscosity neurological effects): the CBD protocol combines TRPV1/CB2 (PV aquagenic pruritus and erythromelalgia) with adenosine/ANS (POTS position-change tachycardia) and 5-HT1A (both thrombotic vigilance from PV and morning dread from POTS) — the mechanisms are additive and there is no conflict between the PV and POTS protocols, since CBD addresses both through different receptor pathways simultaneously. For the medication profile: if the patient is on both ruxolitinib (PV) and ivabradine (POTS), the combined CYP3A4 substrate load from two medications means the CBD CYP3A4 inhibition applies to both simultaneously — a situation requiring dual-specialist coordination (hematologist and POTS cardiologist/electrophysiologist) for CBD disclosure and monitoring. This multi-specialist PV-POTS overlap scenario is the most complex CBD interaction coordination scenario described in this section of the series, though it is rare in clinical practice.
Related Articles
- → CBD Oil for Sleep and Systemic Mastocytosis: KIT D816V Clonal Mast Cells, Bone Marrow Skeletal Pain, Hepatosplenomegaly, and the Midostaurin/Avapritinib CYP3A4 Protocol
- → CBD Oil for Sleep and Mast Cell Activation Syndrome: Nocturnal Mediator Release, Circadian Mast Cell Biology, and the CB2 Direct Mast Cell Receptor Protocol
- → CBD Oil for Sleep and POTS: Position-Change Tachycardia, Hyperadrenergic Arousal, and the Adenosine ANS Parasympathetic Protocol
- → CBD Oil for Sleep and Chronic Pain: TRPV1 Desensitization, CB2 Anti-Inflammatory, and the Nocturnal Pain Arousal Protocol
- → CBD Oil for Sleep and Chronic Itch: Nocturnal Pruritus, TRPV1 Sensory Neuron Sensitization, and the Itch-Sleep Disruption Protocol
References
- Blessing EM, et al. Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics. 2015;12(4):825–836. PMID: 26341731
- Shannon S, et al. Cannabidiol in Anxiety and Sleep: A Large Case Series. Perm J. 2019;23:18–041. PMID: 30624194
- Russo EB. Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag. 2016;4(1):245–259. PMID: 28861491
- Crippa JA, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder. J Psychopharmacol. 2011;25(1):121–130. PMID: 20829306
- Corroon J, Phillips JA. A Cross-Sectional Study of Cannabidiol Users. Cannabis Cannabinoid Res. 2018;3(1):152–161. PMID: 30014049
- Capano A, et al. Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients. Postgrad Med. 2020;132(1):56–61. PMID: 31711352
Medical Disclaimer
This article is for informational and educational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease or medical condition, including polycythemia vera. CBD oil is not a substitute for hematologist-directed PV management, cytoreductive therapy, phlebotomy, or prescribed antiplatelet or anticoagulant medications. Patients on ruxolitinib must consult their hematologist before using CBD due to CYP3A4 pharmacokinetic interaction and potential for enhanced cytopenias. Patients on warfarin or direct oral anticoagulants for prior thrombotic events must consult their hematologist or thrombologist before using CBD due to CYP2C9 and CYP3A4 interactions and bleeding risk. CBD does not treat polycythemia vera, reduce hematocrit, or replace phlebotomy, and does not reduce the thrombotic risk intrinsic to PV. The statements in this article have not been evaluated by the Food and Drug Administration. CBD products are not intended to diagnose, treat, cure, or prevent any disease. Individual responses to CBD vary significantly.
